De RERO Explore à swisscovery: Le 9 décembre 2020, les bibliothèques d’Explore RERO Fribourg (excepté les bibliothèques de Bulle) rejoindront le réseau SLSP (Swiss Library Service Platform). Voir les implications et nouveautés de ce changement.
BCU-Centrale : Prêt entre bibliothèques fermé: Du 23.10.2020 au 9.12.2020 : les demandes de prêt entre bibliothèques (PEB) portant sur des documents appartenant aux futures bibliothèques SLSP ne seront plus possibles.
Hors campus: Membres de la communauté universitaire ou de la HES-SO: n'oubliez pas d'utiliser le VPN de votre institution pour bénéficier de tous les accès.
Physics of nonlinear optics / Guang S. He, Song H. Liu
Auteur:He, Guang-Sheng Contributeur:Liu, Song Hao Editeur:
Singapore [etc.] : World Scientific
XXII, 552 p. : ill. ; 23 cm
Classification:LC QC446.2 Identifiant:
9810233191 (ISBN) No RERO:
Titre: Change and significance of Th22 cells in patients with aplastic anemia Auteur:Liu, Li-Min; Zhang, Xing-Xia; Zhao, Guang-Sheng; Si, Ye-Jun; Lin, Guo-Qiang; Zhang, Yan-Ming; He, Guang-Sheng; Wu, De-Pei Sujet:Anemia, Aplastic -- Pathology ; Interleukins -- Blood ; T-Lymphocytes, Helper-Inducer -- Cytology Description:
To explore the proportion of Th22 cells in peripheral blood of patients with aplastic anemia (AA) and evaluate its significance. From January 2011 to June 2012, a total of 47 AA patients were recruited and divided into 4 groups: severe aplastic anemia (SAA) pre-therapy (group A, n = 11), non-severe aplastic anemia (NSAA) pre-therapy (group B, n = 12), SAA post-therapy (group C, n = 12), NSAA post-therapy (group D, n = 12) and healthy donor controls (n = 12). The proportion of Th22 cells in peripheral blood of each group was evaluated by flow cytometry. The cytokines interleukin-22 (IL-22), transforming growth factor-β (TGF-β), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) were measured by ELISA. And the level of IL-22 mRNA was examined by reverse transcription-PCR (RT-PCR). The percentage of Th22 cells and the level of IL-22, TNF-α, IL-6 and IL-22 mRNA in group A (4.3% ± 1.4%, (57 ± 17) ng/L, (497 ± 123) ng/L, (323 ± 88) ng/L, 1.65 ± 0.51) and group C (2.6% ± 0.6%, (34 ± 10) ng/L, (314 ± 79) ng/L, (187 ± 45) ng/L, 0.92 ± 0.28) were significantly higher than that in control group (1.2% ± 0.3%, (19 ± 6) ng/L, (228 ± 50) ng/L, (134 ± 26) ng/L, 0.47 ± 0.09,all P < 0.05). The percentage of Th22 cells and the level of IL-22, TNF-α , IL-6 and IL-22 mRNA in group A were higher than those in group C (all P < 0.05). NSAA patients had similar results. The percentage of Th22 cells and the level of IL-22, TNF-α , IL-6 and IL-22 mRNA in group A were higher than those in group B (all P < 0.05). But the level of TGF-β in groups A and C were significantly lower than that in control group ((3.4 ± 1.1) and (5.8 ± 1.7) vs (9.7 ± 2.8) ng/L, P < 0.05). And the level of TGF-β in group A was lower than that of group B (P < 0.05).
Fait partie de:
Zhonghua yi xue za zhi, 28 May 2013, Vol.93(20), pp.1537-40
0376-2491 (ISSN); 24028718 Version (PMID)
Titre: Analysis of high risk factors for relapse of leukemia after allogeneic hematopoietic stem cell transplantation Auteur:Chen, Jia; Chen, Feng; Sun, Aining; Qiu, Hui-Ying; Han, Yue; Tang, Xiao-Wen; Fu, Zheng-Zheng; Miao, Miao; He, Guang-Sheng; Jin, Zheng-Ming; Wu, De-Pei Sujet:Hematopoietic Stem Cell Transplantation ; Leukemia -- Pathology Description:
To screen the high risk factors for relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) respectively, then to compare the contribution of each risk factor to relapse and investigate the relevant mechanisms. A retrospective study from single center involved in 262 evaluable cases of leukemia received allo-HSCT over the past 8 years, of them 69 cases with ALL, 90 AML (except APL) and 103 CML. Cox proportional hazard regression model was used for univariate and multivariate analysis to screen the high risk factors. The risk factors significantly affecting relapse in ALL included: Cytogenetic risk classification, the cycles of initial induction chemotherapy; AML: Cytogenetic risk classification, minimal residual disease (MRD) level before transplant, reconstitution of WBC, and CD4(+)/CD8(+) lymphocyte ratio in the graft; CML: disease stage before transplant. The relapse risk after HSCT of ALL mainly depends on the grade of malignancies, and the relapse risk of AML is closely related to the course of transplant. Chronic phase of CML favors a good prognosis after HSCT. Cytogenetic risk classification is the most relevant predictor of relapse after HSCT.
Fait partie de:
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, November 2011, Vol.32(11), pp.729-33
0253-2727 (ISSN); 22339905 Version (PMID)
Titre: Multivariate analysis of imatinib resistance-related factors during the treatment of chronic myeloid leukemia Auteur:Zhou, Min; Qiu, Hui-Ying; He, Guang-Sheng; Xu, Yang; Cen, Jian-Nong; Pan, Jin-Lan; Chen, Su-Ning; Sun, Ai-Ning; Zhang, Ri; Wu, De-Pei Sujet:Drug Resistance, Neoplasm ; Benzamides -- Therapeutic Use ; Leukemia, Myeloid, Chronic-Phase -- Drug Therapy ; Piperazines -- Therapeutic Use ; Pyrimidines -- Therapeutic Use Description:
To explore efficacy of imatinib for patients with chronic myeloid leukemia(CML) and its resistance-related factors during the treatment. The clinical data of 214 CML patients received imatinib were analyzed respectively in our hospital from April 2005 to December 2010. The therapy history and efficacy of regular follow-up and factors influencing drug resistance were analyzed. COX regression analysis was used to perform the univariate and multivariate analysis. Until the end of follow up, thirty-one patients (14.5%) occurred drug resistance. One of them was in accelerated phase(AP), and two in blast phase(BP); 69.2% of patients achieved a complete cytogenetic response(CCyR), and 31.3% of patients achieved a major molecular response(MMR). COX analysis was performed in 207 chronic phase(CP) patients. Univariate analysis showed that the course of disease before treatment, the hemoglobin count, the white blood cell count, whether achieved CCyR or not and whether achieved MMR or not were the influencing factors for imatinib resistance. Multivariate analysis showed that whether achieved CCyR or not was the independent factor for drug resistance. Whether achieved CCyR or not is an independent factor and also a protective factor for imatinib resistance in patients with CML.
Fait partie de:
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, May 2013, Vol.34(5), pp.395-8
0253-2727 (ISSN); 23688748 Version (PMID); 10.3760/cma.j.issn.0253-2727.2013.05.004 (DOI)
Titre: The significance of change of Th22 cells in patients with acute lymphoblastic leukemia Auteur:Liu, Li-Min; Zhang, Xing-Xia; Zhao, Guang-Sheng; Si, Ye-Jun; Lin, Guo-Qiang; Zhang, Yan-Ming; He, Guang-Sheng; Wu, De-Pei Sujet:Interleukins -- Metabolism ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma -- Blood ; T-Lymphocytes, Helper-Inducer -- Metabolism Description:
To investigate the proportion of Th22 cells in peripheral blood of patients with acute lymphoblastic leukemia (ALL) and evaluate its significance. The proportions of Th22 cells in peripheral blood of B-ALL and T-ALL patients before therapy (group 1), B-ALL and T-ALL patients in complete remission (ALL-CR, group 2) and healthy donors (group 3) were evaluated by flow cytometry. The cytokines IL-22, TGF-β, TNF-α and IL-6 in peripheral blood of each group were measured by enzyme-linked immunosorbent assay (ELISA). The levels of IL-22 mRNA in peripheral blood mononuclear cells of each group were examined by reverse transcription-PCR (RT-PCR). The percentages of Th22 cells and the levels of IL-22, TNF-α, IL-6 and IL-22 mRNA in B-ALL and T-ALL patients before therapy were (0.44 ± 0.10)%, (10.9 ± 3.4) ng/L, (110.7 ± 26.5) ng/L, (60.2 ± 13.8) ng/L, 0.17 ± 0.04 and (0.46 ± 0.11)%, (11.2 ± 3.5) ng/L, (114.6 ± 27.0) ng/L, (58.7 ± 12.4) ng/L, 0.19 ± 0.04, respectively; Which in B-ALL and T-ALL patients in complete remission were(0.59 ± 0.15)%, (14.3 ± 4.1) ng/L, (142.5 ± 32.7) ng/L, (83.7 ± 18.9) ng/L, 0.25 ± 0.06 and(0.60 ± 0.15)%, (14.6 ± 4.3) ng/L, (140.4 ± 31.4) ng/L, (81.4 ± 18.2) ng/L, 0.26 ± 0.06, significantly lower than those in healthy donors \[(1.24 ± 0.31)%, (19.7 ± 6.6) ng/L, (238.3 ± 50.4) ng/L, (138.0 ± 27.1) ng/L, 0.49 ± 0.09\] (P 0.05). But the levels of TGF-β in B-ALL and T-ALL patients before therapy \[(30.6...
Fait partie de:
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, December 2012, Vol.33(12), pp.985-8
0253-2727 (ISSN); 23363787 Version (PMID)
Titre: Lower risk myelodysplastic syndrome patients with transfusion dependent treated by dose-reduced decitabine Auteur:Fang, Bao-Zhi; Liu, Zhen-Zhen; He, Guang-Sheng; Miao, Miao; Wang, Xiu-Li; Qiu, Hui-Ying; Jin, Zheng-Ming; Tang, Xiao-Wen; Han, Yue; Fu, Zheng-Zheng; Ma, Xiao; Sun, Ai-Ning; Wu, De-Pei; Ruan, Chang-Geng Sujet:Azacitidine -- Analogs & Derivatives ; Myelodysplastic Syndromes -- Drug Therapy Description:
To evaluate the efficacy and safety of dose-reduced decitabine for the lower risk myelodysplastic syndrome (MDS) patients with transfusion dependent. Twenty-five cases of lower risk (low or intermediate-1 risk in IPSS risk group) MDS patients with transfusion dependence from November 2009 to September 2012 were treated by dose-reduced decitabine (20 mg/m(2) intravenously once daily for 3 days). And their efficacy, side effects, quality-of-life and survival rate were evaluated. Among them, the responses included complete remission (CR, n = 3, 12%), transfusion independence (n = 4, 16%), hematologic improvement (HI, n = 8, 32%) and stable disease (SD, n = 2, 8%). And the overall response rate (ORR) was 68% (17/25) . Among 11 cases available for cytogenetic evaluation, 1 achieved partial cytogenetic remission (PRc). IV grade hematologic toxicity rate was 48% (12/25) and III-IV grade infection rate 20% (5/25). No severe hematologic toxicity was observed. After treatment, the Karnofsky performance score (KPS) increased from 47 ± 16 to 66 ± 22 (P = 0.001); more patients were reclassified as WPSS ≤ 1 (44%vs 16%, P = 0.031) or MDACC score ≤ 7 (64% vs 8%, P = 0.022). The median follow-up time was 467(14-881) d. The 100 and 600-day expected survive rates of low and intermediate -1 risk in IPSS risk group were 100% versus 95.2% and 100% versus 90.5%. Dose-reduced decitabine is well-tolerated and effective in transfusion dependent MDS patients in IPSS-lower risk. There is a low rate of severe hematologic toxicity and early mortality. It may prolong their survival time.
Fait partie de:
Zhonghua yi xue za zhi, 29 October 2013, Vol.93(40), pp.3189-92
0376-2491 (ISSN); 24405538 Version (PMID)
Titre: The variation and clinical significance of paroxysmal nocturnal hemoglobinuria clone in patients with aplastic anemia before and after immunosuppressive therapy Auteur:Sun, Ying-Xin; Zhu, Ming-Qing; He, Guang-Sheng; Wang, Xiu-Li; Fang, Bao-Zhi; Lu, Cong; Liu, Zhen-Zhen; Wu, Qian; Yang, Yong; Wu, De-Pei; Sun, Ai-Ning Sujet:Anemia, Aplastic -- Complications ; Hemoglobinuria, Paroxysmal -- Etiology Description:
To evaluate the evolution of paroxysmal nocturnal hemoglobinuria (PNH) clone and its clinical significance before and after immunosuppressive therapy (IST) in patients with aplastic anemia (AA). A total of 186 patients diagnosed as AA were enrolled in this study. Among them, 55 patients were diagnosed as severe AA (SAA) and treated with cyclosporine (CsA) plus anti-thymocyte globulin (ATG), 131 were diagnosed as non SAA (NSAA) and treated with CsA alone. All patients were screened for PNH clone by flow cytometry before treatment and followed up for 18-76 months, with a median time of 22 months. Positive PNH clones were detected in 10 SAA (18.9%) patients, significantly more than that of NSAA group [9 patients (7.4%), t = 5.041, P = 0.025]. The proportions of PNH clones in SAA group at 6, 12, 24 and > 24 months were 13.38%, 14.88%, 20.00% and 18.85%, respectively, also significantly higher than those of NSAA patients (5.67%, 5.31%, 5.47% and 9.08%, all P values < 0.05). Clinical response rates were comparable in both ATG+CsA or CsA alone groups no matter PNH clone was positive or negative. PNH clone are detectable in AA patients either treated with ATG plus CsA or CsA alone, and more significant by ATG plus CsA. Whether PNH clone occurred before or after IST does not affect the therapeutic efficacy.
Fait partie de:
Zhonghua nei ke za zhi, July 2013, Vol.52(7), pp.585-9
0578-1426 (ISSN); 24267002 Version (PMID)
Titre: Study on the clinical characteristics of 32 patients with mixed phenotype acute leukemia Auteur:Zhang, Yan-Ming; Wu, De-Pei; Sun, Ai-Ning; Qiu, Hui-Ying; Sun, Yu-Mei; He, Guang-Sheng; Jin, Zheng-Ming; Tang, Xiao-Wen; Miao, Miao; Fu, Zheng-Zheng; Han, Yue; Chen, Su-Ning; Zhu, Ming-Qing Sujet:Leukemia, Biphenotypic, Acute -- Genetics Description:
To investigate the clinical and biological characteristics and prognosis of mixed phenotype acute leukemia (MPAL). Thirty two patients were diagnosed as MPAL by bone marrow examination, immunophenotyping, cytogenetic and molecular assay and were treated with combined chemotherapy regimens for both acute lymphoblastic and acute myeloid leukemia. Two cases were received allogeneic hematopoietic stem cell transplantation (allo-HSCT). (1) The incidence of MPAL in acute leukemias was 2.6%. There were 16 cases (50.0%) of mixed myeloid and B-lymphoid (M/B), 14(43.8%) myeloid and T-lymphoid (M/T), one each (3.1%) of trilineage (M/B/T) and B- and T-lymphoid (B/T) phenotype. (2) The positive rates of CD34 and HLA-DR were 87.5% and 62.5%, respectively. (3) Abnormal karyotypes were detected in 70.0% of 30 MPAL patients, which were structural and numerical abnormalities including t(9;22), 11q23 and complex karyotypes. (4) The total complete remission (CR) rate was 75.0% and the overall survival (OS) and disease-free survival (DFS) at 2 years were 14.8% and 14.2% respectively. The CR rates for M/B and M/T cases were 75.0% and 71.4% respectively. No statistical difference was observed in OS and DFS between M/B and M/T cases. MPAL is a rare type of acute leukemia with a high heterogeneity. The unfavorable indicators of MPAL may be factors such as abnormal karyotypes, high expression of CD34 and extramedullary infiltration. Combined regimens and more intensive therapy including allo-HSCT might contribute to improving survival.
Fait partie de:
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, January 2011, Vol.32(1), pp.12-6
0253-2727 (ISSN); 21429394 Version (PMID)
Titre: Impact of induced therapy before allogeneic hematopoietic stem-cell transplantation for higher-risk myelodysplastic syndrome: experience of single centre Auteur:Zhou, Jin-Yi; He, Guang-Sheng; Wu, De-Pei; Sun, Ai-Ning; Qiu, Hui-Ying; Jin, Zheng-Ming; Tang, Xiao-Wen; Han, Yue; Fu, Zheng-Zheng; Ma, Xiao; Miao, Miao; Xue, Sheng-Li; Wang, Ying Sujet:Transplantation Conditioning ; Hematopoietic Stem Cell Transplantation -- Methods ; Myelodysplastic Syndromes -- Therapy Description:
To explore the impact of prior-to-transplantation induction therapy (IT) on patient outcome after allogeneic hematopoietic stem-cell transplantation (Allo-HSCT) for higher-risk myelodysplastic syndromes (MDS). A total of 49 consecutive patients underwent Allo-HSCT for MDS between November 2002 and December 2012. Twenty-six lower-risk MDS cases received supportive therapy (ST). And 17/23 cases of higher-risk MDS received IT prior to transplantation while another 6 only with ST. Their survival, relapse rate and incidence of transplantation-related mortality (TRM) were retrospectively analyzed according to International Prognostic Scoring System (IPSS) scores and marrow blast count. The 5-year cumulative overall survival (OS), disease-free survival (DFS), relapse rate and incidence of transplantation related mortality (TRM) were 59.9%, 59.2%, 10.5% and 31.8% during a median follow-up period of 24.4 (6.2-72.0) months. The OS and DFS of higher-risk group with IT, ST and lower-risk group were different (72.1% vs 16.7% vs 68.1%, P = 0.028; 72.1% vs 16.7% vs 67.9%, P = 0.030). And the OS and DFS of higher-risk group with IT were similar to those of lower-risk group (P = 0.526,0.504) . For the higher-risk group, the patients on IT had improved survival than those on ST in terms of OS and DFS (both P = 0.020). Moreover, the OS and DFS of remission group were higher than non-remission group in patients on IT (both 100% vs 46.7%, P = 0.049). The number of marrow blasts significantly decreased after IT (P = 0.010) without increased TRM (28.9% vs 33.6%, P = 0.612). Induction therapy prior to Allo-HSCT for MDS may reduce clone burden and improve the outcomes of higher-risk MDS without increased TRM.
Fait partie de:
Zhonghua yi xue za zhi, 29 October 2013, Vol.93(40), pp.3185-8
0376-2491 (ISSN); 24405537 Version (PMID)